Akebia Therapeutics (AKBA) Metrics: History & Chart

Akebia Therapeutics, Inc.(AKBA)

Biotechnology · Waltham, MA

$0.89-0.02 (-1.87%)

Delayed quote: Oct 6, 2026, 12:20 PM EDT

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Waltham, MA

194 employees

www.akebia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Butler

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	+1.95%
30D Total Return	-6.59%
YTD Total Return	-43.45%
1Y Total Return	-67.83%
3Y Total Return	-11.61%
5Y Total Return	-67.37%
10Y Total Return	-89.95%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-43.45%
2025	-15.26%
2024	+53.23%
2023	+114.90%
2022	-74.47%
2021	-19.29%
2020

CAGR TTM	-67.65%
CAGR 3Y	-4.03%
CAGR 5Y	-20.07%
CAGR 10Y	-20.53%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

AKBA Valuation Metrics

AKBA Stock Price Metrics

AKBA Dividend Metrics

AKBA Growth Rate Metrics

AKBA Discounted Cash Flow Metrics

AKBA Returns By Period

AKBA Yearly Returns

AKBA Average Annual Returns By Period (CAGR)

AKBA Revenue Metrics

AKBA PE Ratio Metrics

AKBA PS Ratio Metrics

AKBA PB Ratio Metrics

AKBA Price to Free Cash Flow Ratio Metrics

AKBA Debt to Equity Ratio Metrics

AKBA PEG Ratio Metrics

AKBA FCF Yield

AKBA Earnings Yield

AKBA EBITDA Yield

AKBA OCF Yield

AKBA EV/EBIT Ratio Metrics

AKBA EV/EBITDA Ratio Metrics

AKBA EV/Assets Ratio Metrics

AKBA EV/Sales Ratio Metrics

AKBA Current Ratio Metrics

AKBA Quick Ratio Metrics

AKBA ROIC Metrics

AKBA Return on Assets Metrics

AKBA Return on Equity Metrics

AKBA Net Profit Margin Metrics

AKBA Gross Profit Margin Metrics

AKBA Tax Rate Metrics

PS Ratio	1.12
PS Ratio Avg TTM	1.53
PS Ratio Avg 3Y	1.89
Current VS TTM Avg	-26.87%
Current VS 3Y Avg	-40.76%
Current VS 5Y Avg	-20.56%

PB Ratio	9.81
PB Ratio Avg TTM	10.55
PB Ratio Avg 3Y	17.68
Current VS TTM Avg	-7.03%
Current VS 3Y Avg	-44.50%
Current VS 5Y Avg	+18.55%

PFCF Ratio	6.11
PFCF Ratio Avg TTM	7.87
PFCF Ratio Avg 3Y	7.87
Current VS TTM Avg	-22.38%
Current VS 3Y Avg	-22.38%
Current VS 5Y Avg	-22.38%

Debt/Equity Ratio	2.16
Debt/Equity Ratio Avg TTM	1.46
Debt/Equity Ratio Avg 3Y	(0.68)
Current VS TTM Avg	+47.90%
Current VS 3Y Avg	+419.32%
Current VS 5Y Avg	+970.43%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	16.37%
FCF Yield Avg TTM	15.02%
FCF Yield Avg 3Y	15.02%
Current VS TTM Avg	+8.96%
Current VS 3Y Avg	+8.96%
Current VS 5Y Avg	+8.96%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	36.74
Ev/Ebit Ratio Avg TTM	245.87
Ev/Ebit Ratio Avg 3Y	245.87
Current VS TTM Avg	-85.06%
Current VS 3Y Avg	-85.06%
Current VS 5Y Avg	-85.06%

Ev/Ebitda Ratio	29.57
Ev/Ebitda Ratio Avg TTM	19.91
Ev/Ebitda Ratio Avg 3Y	83.14
Current VS TTM Avg	+48.52%
Current VS 3Y Avg	-64.43%
Current VS 5Y Avg	-64.43%

Ev/Assets Ratio	0.41
Ev/Assets Ratio Avg TTM	0.62
Ev/Assets Ratio Avg 3Y	1.42
Current VS TTM Avg	-34.16%
Current VS 3Y Avg	-71.03%
Current VS 5Y Avg	-60.84%

Ev/Sales Ratio	0.66
Ev/Sales Ratio Avg TTM	0.97
Ev/Sales Ratio Avg 3Y	1.98
Current VS TTM Avg	-31.84%
Current VS 3Y Avg	-66.70%
Current VS 5Y Avg	-52.93%

Current Ratio	1.43
Current Ratio Avg TTM	1.66
Current Ratio Avg 3Y	1.48
Current VS TTM Avg	-13.97%
Current VS 3Y Avg	-3.85%
Current VS 5Y Avg	-4.77%

Quick Ratio	1.35
Quick Ratio Avg TTM	1.55
Quick Ratio Avg 3Y	1.30
Current VS TTM Avg	-13.28%
Current VS 3Y Avg	+3.92%
Current VS 5Y Avg	+2.79%

ROIC	(7.08%)
ROIC Avg 3Y	(16.76%)
ROIC Avg 5Y	(29.87%)
Current VS 3Y Avg	+57.76%
Current VS 5Y Avg	+76.29%
Current VS 10Y Avg	+83.89%

ROA	(8.48%)
ROA Avg TTM	(1.62%)
ROA Avg 3Y	(3.72%)
Current VS TTM Avg	-424.95%
Current VS 3Y Avg	-128.22%
Current VS 5Y Avg	-54.56%

ROE	(118.58%)
ROE Avg TTM	(74.60%)
ROE Avg 3Y	(92.89%)
Current VS TTM Avg	-58.96%
Current VS 3Y Avg	-27.66%
Current VS 5Y Avg	+25.36%

Net Profit Margin	(13.54%)
Net Profit Margin Avg TTM	(11.00%)
Net Profit Margin Avg 3Y	(21.15%)
Current VS TTM Avg	-23.14%
Current VS 3Y Avg	+35.97%
Current VS 5Y Avg	+65.63%

Gross Profit Margin	79.48%
Gross Pft Margin Avg TTM	80.33%
Gross Pft Margin Avg 3Y	74.82%
Current VS TTM Avg	-1.05%
Current VS 3Y Avg	+6.23%
Current VS 5Y Avg	+13.87%

Tax Rate	53.25%
Tax Rate Avg 3Y	13.31%
Tax Rate Avg 5Y	10.65%
Current VS 3Y Avg	+300.00%
Current VS 5Y Avg	+400.00%
Current VS 10Y Avg	+500.00%